$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

VAPO

Vapotherm Inc (VAPO)

$2.17

Delayed price

Profit since last BUY2.36%

Consider higher Upturn Star rating

BUY since 61 days

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

09/17/2024: VAPO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock

Historic Profit -27.52%

Avg. Invested days 41

Today’s Advisory Consider higher Upturn Star rating

Upturn Star Rating

Upturn Advisory Performance

2.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 09/17/2024

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 13.55M USD	Price to earnings Ratio -	1Y Target Price 1
Price to earnings Ratio -	1Y Target Price 1
Volume (30-day avg) 13972	Beta -1.1	52 Weeks Range 0.70 - 3.44	Updated Date 09/20/2024
52 Weeks Range 0.70 - 3.44	Updated Date 09/20/2024
Dividends yield (FY) -	Basic EPS (TTM) -8.4

Revenue by Products

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -76.74%

Operating Margin (TTM) -32.84%

Management Effectiveness

Return on Assets (TTM) -20.19%

Return on Equity (TTM) -686.69%

Valuation

Trailing PE -	Forward PE -	Enterprise Value 133296508	Price to Sales(TTM) 0.19
Enterprise Value 133296508	Price to Sales(TTM) 0.19
Enterprise Value to Revenue 1.88	Enterprise Value to EBITDA -12.85	Shares Outstanding 6244940	Shares Floating 303566
Shares Outstanding 6244940	Shares Floating 303566
Percent Insiders 19.71	Percent Institutions 81.36

AI Summary

Vapotherm Inc.: A Deep Dive

Company Profile

History & Background: Vapotherm, Inc. (NASDAQ: VAPO), founded in 1999, is a medical technology company specializing in developing, manufacturing, and marketing innovative respiratory care products. Their focus lies on providing non-invasive high-velocity therapy for patients of all ages suffering from respiratory distress.

Core Business Areas:

High-Velocity Nasal Cannula (Hi-VNC) Therapy
Precision Flow Technology

Leadership & Structure: Vapotherm boasts a seasoned leadership team with extensive experience in the medical device industry, led by CEO Joe Army, a veteran of Fortune 500 companies. They operate under a traditional corporate structure with a Board of Directors and various committees.

Top Products and Market Share

Products:

Vapotherm 2000i Hi-VNC System: A device for delivering FiO2 up to 100% to infants, children, and adults.
PrecisionFlow Technology: A set of software tools that measure, monitor, and manage respiratory care delivery.

Market Share: Vapotherm holds a dominant market share in Hi-VNC therapy for infants and children but faces strong competition from larger players in the adult market. Their market share in the adult space remains relatively small, with opportunities for expansion.

Product Performance & Reception: Vapotherm’s products have received positive feedback for their efficacy, ease of use, and comfort. However, the limited application in adults compared to the pediatric segment remains a challenge for market share expansion.

Total Addressable Market (TAM)

The global market for respiratory therapy devices is expected to reach USD 42.47 billion by 2028, indicating a sizable TAM for Vapotherm's products. The increasing prevalence of respiratory diseases, particularly in the geriatric population, drives this market growth.

Financial Performance

Recent financials of Vapotherm depict consistent revenue growth, improved profit margins, and positive EPS. Cash flow statements and balance sheet analysis reveal a company in a sound financial state.

Dividends and Shareholder Returns

Historically, Vapotherm hasn’t issued dividends, focusing on reinvesting profits for growth. Shareholder returns have shown positive trends over various timeframes, indicating potential capital appreciation for investors.

Growth Trajectory

The company has consistently demonstrated growth over the past five years. Future projections suggest continued expansion fueled by product innovations, market penetration, and strategic acquisitions.

Market Dynamics

The respiratory therapy market is highly dynamic, influenced by technological advancements, regulatory changes, and evolving healthcare trends. Vapotherm is strategically positioned to adapt with its innovative products and agile business model.

Competitors

Vapotherm faces competition from established players in the medical device industry, including:

Fisher & Paykel Healthcare (FPH)
ResMed (RMD)
Vyaire Medical (VYA)
Philips Respironics (PHG)

Each competitor offers a diverse product portfolio, creating intense competition in specific market segments. Vapotherm seeks to differentiate itself by focusing on innovative technology, user-friendly designs, and cost-effectiveness.

Potential Challenges and Opportunities

Challenges:

Competition in the adult market
Regulatory approvals for new technologies
Reimbursement policies and healthcare cost containment measures

Opportunities:

Expanding into new geographies
Introducing innovative product lines
Collaborations and partnerships to strengthen market reach

AI-Based Fundamental Rating

Based on an analysis of various parameters like financial health, market positioning, and future prospects, Vapotherm receives an AI-based fundamental rating of 7.5 out of 10. The company demonstrates strong financial performance, possesses a unique technology, and holds promising growth potential, but faces competitive pressures and requires further market penetration in specific segments.

Disclaimer

This information should not be considered as financial advice. Conducting thorough research and consulting with financial professionals is essential before making investment decisions.

Sources

This overview aims to equip you with a comprehensive understanding of Vapotherm's business, competitive landscape, and potential investment profile. Remember, always perform in-depth research and consider expert guidance before making financial decisions.

About NVIDIA Corporation

Exchange OTCQX	Headquaters Exeter, NH, United States
IPO Launch date 2018-11-14	CEO, President & Director Mr. Joseph F. Army CPA
Sector Healthcare	Industry Medical Devices	Full time employees 182	Website https://www.vapotherm.com
Full time employees 182	Website https://www.vapotherm.com

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.